DoMore Diagnostics featured in Oslo Cancer Cluster Start-up Spotlight series

OSLO – December 11, 2024 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine in cancer, is featured in an article that is a part of the Start-up Spotlight series published by Oslo Cancer Cluster.

This article highlights the AI-powered digital biomarker Histotype Px® Colorectal that enables personalized treatment decisions for colorectal cancer patients to ensure they receive the appropriate care and minimize toxicity.

"Currently, only 2-20% of patients treated with chemotherapy after surgery actually benefit from this toxic treatment leading to unnecessary side effects and increased healthcare costs," says CEO and Co-Founder Torbjørn Furuseth. "Our solution aims to better identify the patients who truly benefit from the treatment, improving outcomes while minimizing harm."

This article series is produced by the Norwegian health clusters Oslo Cancer Cluster, Norway Health Tech, Norwegian Smart Care Cluster, The Life Science Cluster, and Biotech North, funded by Viken Fylkeskommune.

Click here to read the full article.

About DoMore Diagnostics

DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.

About Colorectal Cancer and Histotype Px® Colorectal

Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment in the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefiting from ACT and only suffering side effects.

Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.

For more information, please visit:

www.domorediagnostics.com
LinkedIn
The Lancet publication
The Lancet Oncology publication

Contact:

Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com

Next
Next

DoMore Diagnostics welcomes Dr. Lao Saal as our new consulting Medical Director